Home › Non-Small Cell Lung Cancer › North Carolina › Raleigh
Non-Small Cell Lung Cancer clinical trials in Raleigh, NC
4 studies for Non-Small Cell Lung Cancer are looking for participants at sites in and around Raleigh (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
RecruitingPhase 3
- WakeMed Raleigh Campus ( Site 3214), Raleigh
A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
RecruitingPhase 3
- WakeMed Raleigh Campus ( Site 0144), Raleigh
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RecruitingPhase 3
- Duke Cancer Center Raleigh, Raleigh
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
RecruitingPhase 3
- WakeMed Raleigh Campus, Raleigh
Non-Small Cell Lung Cancer trials in other cities
- Houston, TX145 studies
- New York City, NY121 studies
- Arlington, VA104 studies
- Nashville, TN97 studies
- Boston, MA90 studies
- Los Angeles, CA87 studies
- St. Louis, MO73 studies
- Chicago, IL61 studies
- Baltimore, MD60 studies
- San Antonio, TX59 studies
- Columbus, OH57 studies
- Washington, DC55 studies
Other studies in Raleigh
- Heart Failure7 studies
- Coronary Artery Disease6 studies
- Obesity6 studies
- Type 2 Diabetes6 studies
- Macular Degeneration6 studies
- Atherosclerosis5 studies
- Overweight5 studies
- Cardiovascular Disease5 studies
- Endometrial Cancer5 studies
- Stroke5 studies
- Kidney Failure4 studies
- Diabetes4 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.